

James B Bussel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3776884/james-b-bussel-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

339
papers

19,292
citations

69
h-index

135
g-index

363
ext. papers

22,043
ext. citations

5.5
avg. IF

6.96
L-index

#	Paper	IF	Citations
339	Disorders of platelets 2022 , 237-285		
338	Hemolysis after High-Dose Intravenous Immunoglobulin: an Under-Appreciated Sequelae.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
337	Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). <i>Blood</i> , 2021 , 138, 2088-2088	2.2	0
336	Surveillance Program of Romiplostim Use Connected to Pregnancy. <i>Blood</i> , 2021 , 138, 585-585	2.2	1
335	Do Splenectomized Immune Thrombocytopenia (ITP) Patients Have Increased Risks for Platelet Decreases Following COVID-19 Vaccination?. <i>Blood</i> , 2021 , 138, 2090-2090	2.2	
334	Splenectomy Results in Venous Thromboembolic Events in Women: A Nurses Health Study. <i>Blood</i> , 2021 , 138, 3163-3163	2.2	0
333	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 586-586		0
332	LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 1010-1010	2.2	2
331	COVID-19 Vaccination in Adults with Immune Thrombocytopenia (ITP): Data from the Platelet Disorder Support Association (PDSA) Patient Registry. <i>Blood</i> , 2021 , 138, 3164-3164	2.2	1
330	Immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2021 , 1-13	2.8	1
329	Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. <i>American Journal of Hematology</i> , 2021 , 96, 534-537	7.1	183
328	Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e29023	3	1
327	Immune thrombocytopenia during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2021 , 193, 1093-1095	4.5	2
326	A Review of Romiplostim Mechanism of Action and Clinical Applicability. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 2243-2268	4.4	7
325	Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients. <i>ELife</i> , 2021 , 10,	8.9	1
324	COVID-19 vaccination and immune thrombocytopenia. <i>Nature Medicine</i> , 2021 , 27, 1145-1146	50.5	9
323	Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. <i>American Journal of Hematology</i> , 2021 , 96, E373-E376	7.1	1

322	Immune thrombocytopenia (ITP) World Impact Survey (iWISH): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. <i>American Journal of Hematology</i> , 2021 , 96, 188-198	7.1	22
321	Immune thrombocytopenia (ITP) World Impact Survey (I-WISH): Impact of ITP on health-related quality of life. <i>American Journal of Hematology</i> , 2021 , 96, 199-207	7.1	21
320	Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 20406207211010875	5.7	9
319	Fetal and Neonatal Alloimmune Thrombocytopenias 2021 , 223-242		
318	Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study. <i>British Journal of Haematology</i> , 2021 ,	4.5	
317	New developments in fetal and neonatal alloimmune thrombocytopenia. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 225, 120-127	6.4	5
316	Familial thrombocythaemia - a distinct entity from essential thrombocythaemia. <i>British Journal of Haematology</i> , 2021 , 194, 808-809	4.5	1
315	Heritable platelet disorders: an enigma even guidelines can't unravel. <i>British Journal of Haematology</i> , 2021 , 195, 13-14	4.5	
314	SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients. <i>Blood</i> , 2021 ,	2.2	10
313	Fatigue in children and adolescents with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020 , 191, 98-106	4.5	9
312	Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children. <i>British Journal of Haematology</i> , 2020 , 189, e37-e40	4.5	6
311	Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia. <i>Transfusion and Apheresis Science</i> , 2020 , 59, 102712	2.4	7
310	ITP World Impact Survey (I-WISH) 2.0: Further Exploration of the Impact of ITP on Patients. <i>Blood</i> , 2020 , 136, 2-3	2.2	
309	Clinical Outcomes in Patients with Immune Thrombocytopenia Treated with All 3 Approved Thrombopoietin Receptor Agonists. <i>Blood</i> , 2020 , 136, 18-19	2.2	
308	Immune Thrombocytopenia: A Complex Autoimmune Disease 2020 , 911-921		1
307	Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP). <i>British Journal of Haematology</i> , 2020 , 189, 379-382	4.5	2
306	Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. <i>Thrombosis Research</i> , 2020 , 185, 119-124	8.2	11
305	Early combination treatment of immune thrombocytopenia: Is this the way?. <i>American Journal of Hematology</i> , 2020 , 95, 1452-1453	7.1	

304	Identification of occult cerebral microbleeds in adults with immune thrombocytopenia. <i>Blood</i> , 2020 , 136, 2875-2880	2.2	3
303	Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome. <i>Blood Advances</i> , 2020 , 4, 3368-3377	7.8	4
302	Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020 , 190, 933-938	4.5	14
301	Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. <i>Blood Advances</i> , 2020 , 4, 4136-4146	7.8	28
300	Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 146, 467-478	11.5	28
299	Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. <i>Blood</i> , 2020 , 136, 3056-3061	2.2	18
298	Preparing patients with immune thrombocytopenia for surgery: what are the options?. <i>Lancet Haematology</i> , 2020 , 7, e626-e627	14.6	1
297	Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists. <i>Platelets</i> , 2020 , 31, 198-205	3.6	11
296	Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists. <i>Platelets</i> , 2020 , 31, 322-328	3.6	4
295	Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. <i>Haematologica</i> , 2020 , 105, e129-e132	6.6	4
294	Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. <i>Blood</i> , 2020 , 135, 472-490	2.2	38
293	Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. <i>Seminars in Hematology</i> , 2019 , 56, 262-278	4	14
292	Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?. <i>Haematologica</i> , 2019 , 104, 1124-1135	6.6	27
291	FAS mutations are an uncommon cause of immune thrombocytopenia in children and adults without additional features of immunodeficiency. <i>British Journal of Haematology</i> , 2019 , 186, e163-e165	4.5	3
290	Maternal sensitization occurs before delivery in severe cases of fetal alloimmune thrombocytopenia. <i>American Journal of Hematology</i> , 2019 , 94, E213-E215	7.1	3
289	Thrombopoietin receptor agonists: ten years later. <i>Haematologica</i> , 2019 , 104, 1112-1123	6.6	116
288	Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia. <i>American Journal of Hematology</i> , 2019 , 94, E196-E198	7.1	1
287	Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. <i>British Journal of Haematology</i> , 2019 , 185, 549-562	4.5	31

286	Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. <i>Haematologica</i> , 2019 , 104, 2283-2291	6.6	22
285	Immune Thrombocytopenia (ITP) 2019 , 707-724		1
284	Postnatal intervention for the treatment of FNAIT: a systematic review. <i>Journal of Perinatology</i> , 2019 , 39, 1329-1339	3.1	11
283	Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. <i>American Journal of Hematology</i> , 2019 , 94, 741-750	7.1	23
282	Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2019 , 185, 136-139	4.5	7
281	Peri- and Postpartum Management of Patients With Factor XI Deficiency. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619880262	3.3	4
280	Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study. <i>Blood</i> , 2019 , 134, 1081-1081 ⁰	2.2	9
279	Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics. <i>Blood</i> , 2019 , 134, 1090-1090	2.2	9
278	Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients. <i>Blood</i> , 2019 , 134, 1069-1069	2.2	2
277	Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia. <i>Blood</i> , 2019 , 134, 4889-4889	2.2	3
276	Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia. <i>Blood</i> , 2019 , 134, 897-897	2.2	4
275	Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2019 , 134, 1095-1095	2.2	5
274	The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey. <i>Blood</i> , 2019 , 134, 1076-1076	2.2	2
273	Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?. <i>Clinical Hematology International</i> , 2019 , 1, 173-179	1.8	
272	Physicians and Patients Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISH). <i>Blood</i> , 2019 , 134, 1097-1097	2.2	
271	Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry. <i>Blood</i> , 2019 , 134, 2362-2362	2.2	2
270	Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. <i>American Journal of Hematology</i> , 2019 , 94, 546-553	7.1	37
269	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019 , 3, 3780-3817	7.8	267

268	Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2019 , 41, e257-e259	1.2	1
267	Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. <i>British Journal of Haematology</i> , 2019 , 185, 102-106	4.5	8
266	Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. <i>Vox Sanguinis</i> , 2019 , 114, 79-94	3.1	22
265	Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. <i>American Journal of Hematology</i> , 2019 , 94, 200-208	7.1	13
264	Platelet transfusion practices in immune thrombocytopenia related hospitalizations. <i>Transfusion</i> , 2019 , 59, 169-176	2.9	12
263	Fetal and Neonatal Alloimmune Thrombocytopenia 2019 , 581-588		1
262	Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. <i>Platelets</i> , 2019 , 30, 206-212	3.6	9
261	Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment. <i>Platelets</i> , 2019 , 30, 222-228	3.6	1
260	Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018 , 93, 882-888	7.1	23
259	Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. <i>American Journal of Hematology</i> , 2018 , 93, 921-930 ¹	7.1	13 ¹
258	Fostamatinib for persistent/chronic adult immune thrombocytopenia. <i>Immunotherapy</i> , 2018 , 10, 9-25	3.8	37
257	Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. <i>Rheumatology</i> , 2018 , 57, 1432-1438	3.9	17
256	Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim. <i>Blood</i> , 2018 , 132, 735-735	2.2	3
255	Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-WISH). <i>Blood</i> , 2018 , 132, 2273-2273	2.2	9
254	Results from the ITP World IMPACT Survey (I-WISH): Patients with Immune Thrombocytopenia (ITP) Experience Impaired Quality of Life (QoL) Regarding Daily Activities, Social Interactions, Emotional Well-Being and Working Lives. <i>Blood</i> , 2018 , 132, 4804-4804	2.2	4
253	Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials. <i>Blood</i> , 2018 , 132, 3740-3740	2.2	0
252	Two placebo-controlled phase 3 studies of fostamatinib, an oral spleen tyrosine kinase (Syk) inhibitor, for the treatment of persistent/chronic immune thrombocytopenia (ITP) in adults: Analysis of platelet response by prior ITP therapies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15146-e15146	2.2	
251	Thrombin-Generating Capacity of Microvesicles (MVs) in Patients with Immune Thrombocytopenia (ITP) before and during Treatment with Thrombopoietin-Receptor Agonists (TPO-RA). <i>Blood</i> , 2018 , 132, 2511-2511	2.2	

250	Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study. <i>Blood</i> , 2018 , 132, 1152-1152	2.2	152
249	Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding. <i>Blood</i> , 2018 , 132, 4717-4717	2.2	
248	Medical Decision Analysis: Choosing Second Line Treatment in Adults with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2018 , 132, 4986-4986	2.2	
247	Health-related quality of life in adult primary immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2018 , 11, 975-985	2.8	11
246	TPO-mimetics for chemotherapy-induced thrombocytopenia: timing matters. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2763-2764	1.9	1
245	Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	25
244	IVIg and FcγRIIb in kids with ITP: individualizing therapy. <i>Blood</i> , 2018 , 132, 877-878	2.2	2
243	Screening for Wiskott-Aldrich syndrome by flow cytometry. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 333-335.e8	11.5	15
242	Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. <i>Blood</i> , 2017 , 129, 1538-1547	2.2	66
241	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. <i>Haematologica</i> , 2017 , 102, 1192-1203	6.6	67
240	Immune Thrombocytopenia: Where Are We Now? 2017 , 749-760		
239	Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2017 , 92, 730-738	7.1	32
238	Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. <i>Blood</i> , 2017 , 130, 2527-2536	2.2	147
237	TPO for ITP in pregnancy. <i>Blood</i> , 2017 , 130, 1073-1074	2.2	4
236	Imaging and management of fetuses and neonates with alloimmune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26690	3	9
235	Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone. <i>Journal of Pediatrics</i> , 2017 , 191, 225-231	3.6	19
234	Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP). <i>Platelets</i> , 2017 , 28, 478-483	3.6	3
233	Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP). <i>Blood</i> , 2017 , 130, 752-752	2.2	1

232	Platelet count control in immune thrombocytopenic purpura patient: Optimum romiplostim dose profile. <i>Journal of Process Control</i> , 2016 , 45, 76-83	3.9	3
231	Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. <i>American Journal of Hematology</i> , 2016 , 91, 907-11	7.1	31
230	Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim. <i>Hematology</i> , 2016 , 21, 257-62	2.2	19
229	Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. <i>Platelets</i> , 2016 , 27, 472-8	3.6	11
228	Hepatobiliary and Thromboembolic Events during Long-Term E.X.T.E.N.Ded Treatment with Eltrombopag in Adult Patients with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2016 , 128, 1368-1368	2.2	2
227	Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study. <i>Blood</i> , 2016 , 128, 3742-3742	2.2	2
226	Efficacy of Eltrombopag in Adult East Asian and Non-East Asian Patients with Chronic Immune Thrombocytopenia (cITP): Results from the Extend Study. <i>Blood</i> , 2016 , 128, 4930-4930	2.2	3
225	Disorders of Platelets 2016 , 239-278		0
224	Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. <i>Haematologica</i> , 2016 , 101, e237-9	6.6	10
223	Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. <i>Haematologica</i> , 2016 , 101, 1327-1332	6.6	6
222	Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 215, 471.e1-9	6.4	11
221	Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , 2016 , 388, 45-54	4.0	96
220	Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia. <i>Transfusion</i> , 2016 , 56, 2449-2454	2.9	4
219	Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor. <i>British Journal of Haematology</i> , 2016 , 173, 942-5	4.5	13
218	Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. <i>Lancet, The</i> , 2015 , 386, 1649-58	4.0	129
217	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. <i>Lancet Haematology, the</i> , 2015 , 2, e315-25	14.6	112
216	Thrombopoietin receptor agonists: a critical review. <i>Seminars in Hematology</i> , 2015 , 52, 46-52	4	21
215	Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2015 , 62, 208-213	3	51

214	Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. <i>Blood</i> , 2015 , 126, 1367-78	2.2	71
213	Suppression of in vitro megakaryopoiesis by maternal sera containing anti-HPA-1a antibodies. <i>Blood</i> , 2015 , 126, 1234-6	2.2	11
212	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. <i>PLoS Genetics</i> , 2015 , 11, e1005262	6	99
211	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. <i>Blood</i> , 2015 , 126, 73-73	2.2	4
210	Clinical Features of Alloimmune Neutropenia: Composite of 2 Case Series and 39 Case Reports. <i>Blood</i> , 2015 , 126, 4607-4607	2.2	
209	Effects of Anti-Glycoprotein Antibodies on Response of Immune Thrombocytopenia Patients to Thrombopoietin Receptor Agonists and on Megakaryocytes Viability. <i>Blood</i> , 2015 , 126, 1048-1048	2.2	
208	Standard Dose Rituximab and 3 4-Day Cycles of Dexamethasone (R+3D) Appears Curative in Females with ITP <i>Blood</i> , 2015 , 126, 1059-1059	2.2	0
207	Review of fetal and neonatal immune cytopenias. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 35-43	0.6	17
206	Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2014 , 166, 592-600 ^{4.5}		69
205	Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. <i>Journal of Pediatrics</i> , 2014 , 165, 600-5.e4	3.6	44
204	Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. <i>Haematologica</i> , 2014 , 99, 1264-71	6.6	58
203	Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. <i>Haematologica</i> , 2014 , 99, 937-44 ^{6.6}		65
202	Platelet count control in immune thrombocytopenic purpura patient: optimum romiplostim dose profile. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2014 , 47, 11800-11805		2
201	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. <i>Blood</i> , 2014 , 123, 3887-94	2.2	78
200	Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. <i>Blood</i> , 2014 , 124, e4-e10	2.2	93
199	IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens. <i>Blood</i> , 2014 , 124, 3561-71	2.2	36
198	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. <i>Haematologica</i> , 2014 , 99, 1387-94	6.6	52
197	Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. <i>American Journal of Hematology</i> , 2014 , 89, E228-34	7.1	26

196	The new thrombopoietic agenda: impact on leukemias and MDS. <i>Best Practice and Research in Clinical Haematology</i> , 2014 , 27, 288-92	4.2	6
195	Management of thrombocytopenia. <i>F1000prime Reports</i> , 2014 , 6, 45		53
194	Thrombopoietic agents: there is still much to learn. <i>Presse Medicale</i> , 2014 , 43, e69-78	2.2	7
193	PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2014 , 124, 1450-1450	2.2	3
192	Response to TPO-Receptor Agonists: Role of Immature Platelet Fraction and Anti-GP1b. <i>Blood</i> , 2014 , 124, 4190-4190	2.2	1
191	Thrombopoietin Receptor Agonists in Paediatric ITP Patients: Long Term Follow up Data in 34 Patients. <i>Blood</i> , 2014 , 124, 4206-4206	2.2	5
190	Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2014 , 124, 4184-4184	2.2	
189	Classical Pathway of Complement Activation in ITP: Inhibition By TNT003, a Novel C1s Inhibitor. <i>Blood</i> , 2014 , 124, 1453-1453	2.2	1
188	Issues in Categorization and Management of Pediatric Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2014 , 124, 1843-1843	2.2	
187	Enhanced Megakaryocyte Apoptosis Corresponds to Higher Platelet Counts in Immune Thrombocytopenia Patients and Increased Proplatelet Formation in Cell Culture. <i>Blood</i> , 2014 , 124, 5114-5114		
186	Effects of Thrombopoietin Mimetics on Patients with Chronic ITP: Perspectives from Blood Transcriptome Profiling Analysis. <i>Blood</i> , 2014 , 124, 2780-2780	2.2	
185	Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. <i>British Journal of Haematology</i> , 2013 , 162, 693-701	4.5	21
184	Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). <i>British Journal of Haematology</i> , 2013 , 160, 538-46	4.5	45
183	The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP). <i>British Journal of Haematology</i> , 2013 , 160, 237-43	4.5	16
182	Immune Thrombocytopenia (ITP) 2013 , 819-833		4
181	Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. <i>British Journal of Haematology</i> , 2013 , 161, 411-23	4.5	180
180	Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. <i>Blood</i> , 2013 , 121, 537-45	2.2	236
179	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. <i>Blood</i> , 2013 , 121, 2596-606	2.2	126

178	Modified antibody in fetal alloimmunization. <i>Blood</i> , 2013 , 122, 303-4	2.2	2
177	Fetal and Neonatal Alloimmune Thrombocytopenia 2013 , 609-613		1
176	Update On The Safety and Efficacy Of EXTENDED Treatment With Eltrombopag (EPAG) In Adults With Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2013 , 122, 2315-2315	2.2	5
175	Safety and Efficacy Of Eltrombopag At Escalated Doses Up To 150mg In Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive To 75 Mg. <i>Blood</i> , 2013 , 122, 3559-3559	2.2	3
174	Self-administration of romiplostim in patients with chronic immune thrombocytopenia. <i>Community Oncology</i> , 2013 , 10, 285-292		6
173	Cyclosporine-Romiplostim-IVIG Combination Therapy In Patients With Severe Immune Thrombocytopenia (ITP). <i>Blood</i> , 2013 , 122, 1085-1085	2.2	
172	Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP). <i>Blood</i> , 2013 , 122, 3530-3530	2.2	
171	Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. <i>Blood</i> , 2012 , 119, 5989-95	2.2	230
170	Defective regulatory B-cell compartment in patients with immune thrombocytopenia. <i>Blood</i> , 2012 , 120, 3318-25	2.2	127
169	Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. <i>British Journal of Haematology</i> , 2012 , 158, 811-4	4.5	19
168	How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. <i>Blood</i> , 2012 , 120, 960-9	2.2	165
167	In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. <i>Blood</i> , 2012 , 119, 4066-72	2.2	70
166	Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2012 , 58, 395-8	3	33
165	Thrombopoietin-receptor agonists. <i>Current Opinion in Hematology</i> , 2012 , 19, 392-8	3.3	33
164	Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. <i>Modern Pathology</i> , 2012 , 25, 65-74	9.8	30
163	Successful Discontinuation of Eltrombopag Treatment in Patients with Chronic ITP. <i>Blood</i> , 2012 , 120, 1085-1085	2.2	12
162	Dynamics of Improvement in Health-Related Quality of Life (HRQoL) with Long-Term Eltrombopag Treatment in Adults with Chronic Immune Thrombocytopenia (ITP) in EXTEND.. <i>Blood</i> , 2012 , 120, 2199-2199	2.2	19
161	Survey of the Side Effects of ITP Therapies. <i>Blood</i> , 2012 , 120, 3327-3327	2.2	1

160	Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. <i>Lancet, The</i> , 2011 , 377, 393-402	4.0	383
159	Eltrombopag for chronic immune thrombocytopenia [AuthorsPreply. <i>Lancet, The</i> , 2011 , 377, 1919-1920	4.0	
158	Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. <i>Obstetrics and Gynecology</i> , 2011 , 118, 1157-1163	4.9	78
157	A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. <i>Blood</i> , 2011 , 118, 28-36	2.2	168
156	Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. <i>Blood</i> , 2011 , 117, 5723-32	2.2	114
155	Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. <i>British Journal of Haematology</i> , 2011 , 155, 248-55	4.5	29
154	Standard Dose Rituximab Plus 24 Cycles of Pulse Dexamethasone Is Effective and Tolerable in Treatment of Immune Thrombocytopenia (ITP). <i>Blood</i> , 2011 , 118, 1166-1166	2.2	1
153	Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,. <i>Blood</i> , 2011 , 118, 3281-3281	2.2	5
152	Cumulative Response to Eltrombopag and Impact of the Number of Prior ITP Therapies: Interim Results of a Long-Term Extension Study,. <i>Blood</i> , 2011 , 118, 3297-3297	2.2	1
151	Eltrombopag. <i>Cancer Treatment and Research</i> , 2011 , 157, 289-303	3.5	11
150	International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i> , 2010 , 115, 168-86	2.2	1392
149	Thrombopoietic agents in immune thrombocytopenia. <i>Seminars in Hematology</i> , 2010 , 47, 258-65	4	13
148	Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. <i>Blood</i> , 2010 , 116, 4639-45	2.2	207
147	The long-term impact of rituximab for childhood immune thrombocytopenia. <i>Current Rheumatology Reports</i> , 2010 , 12, 94-100	4.9	23
146	Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. <i>American Journal of Obstetrics and Gynecology</i> , 2010 , 203, 135.e1-14	6.4	71
145	Stability of measurement of the immature platelet fraction. <i>American Journal of Hematology</i> , 2010 , 85, 622-4	7.1	21
144	Platelet Function and Response to Thrombopoietin Mimetics In Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.. <i>Blood</i> , 2010 , 116, 1429-1429	2.2	2
143	Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. <i>Haematologica</i> , 2010 , 95, 1807-11	6.6	28

142	The Effect of Eltrombopag on Human Platelet Resistance to Apoptosis: The Role of the Bcl-Xl Pathway. <i>Blood</i> , 2010 , 116, 2520-2520	2.2	
141	The Use of Immature Platelet Fraction to Assess Thrombopoiesis and Mechanisms of Treatment Effect In Immune Thrombocytopenia (ITP). <i>Blood</i> , 2010 , 116, 2513-2513	2.2	
140	Rituximab Maintenance Treatment In Immune Mediated Thrombocytopenia (ITP) Including Evans Syndrome. <i>Blood</i> , 2010 , 116, 2523-2523	2.2	
139	Current approaches to the evaluation and management of the fetus and neonate with immune thrombocytopenia. <i>Seminars in Perinatology</i> , 2009 , 33, 35-42	3.3	77
138	Repeated courses of rituximab in chronic ITP: Three different regimens. <i>American Journal of Hematology</i> , 2009 , 84, 661-5	7.1	46
137	One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. <i>Pediatric Blood and Cancer</i> , 2009 , 52, 259-62	3	44
136	Cytomegalovirus can make immune thrombocytopenic purpura refractory. <i>British Journal of Haematology</i> , 2009 , 146, 104-12	4.5	58
135	Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. <i>Hematology/Oncology Clinics of North America</i> , 2009 , 23, 1329-41	3.1	5
134	The ITP syndrome: pathogenic and clinical diversity. <i>Blood</i> , 2009 , 113, 6511-21	2.2	533
133	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. <i>Blood</i> , 2009 , 113, 2386-93	2.2	1651
132	The changing landscape of secondary ITP: introduction. <i>Seminars in Hematology</i> , 2009 , 46, S1	4	2
131	Therapeutic approaches to secondary immune thrombocytopenic purpura. <i>Seminars in Hematology</i> , 2009 , 46, S44-58	4	11
130	Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009 , 373, 641-8	4.0	412
129	Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 595-9	3.1	32
128	Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. <i>Blood</i> , 2009 , 113, 2161-71	2.2	346
127	Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. <i>Blood</i> , 2009 , 113, 3154-60	2.2	186
126	Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. <i>Blood</i> , 2009 , 113, 1231-40	2.2	210
125	Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. <i>Blood</i> , 2009 , 114, 4777-83	2.2	155

124	Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2009 , 114, 1322-1322	2.2	2
123	3G8 and GMA161, Anti Fc γ RIII Inhibitory Monoclonal Antibodies in the Treatment of Chronic Refractory ITP. (Summary of 2 Pilot Studies).. <i>Blood</i> , 2009 , 114, 2404-2404	2.2	10
122	A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2009 , 114, 680-680	2.2	2
121	Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.. <i>Blood</i> , 2009 , 114, 681-681	2.2	2
120	Long-Term Treatment of Chronic Immune Thrombocytopenic Purpura with Oral Eltrombopag: Results From the EXTEND Study.. <i>Blood</i> , 2009 , 114, 682-682	2.2	6
119	Association Between IgA Immunoglobulin Level and Response to Treatment for Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2009 , 114, 3503-3503	2.2	
118	Time to Splenectomy Failure in Patients with Recurrent or Refractory Chronic Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2009 , 114, 3522-3522	2.2	
117	Update on eltrombopag for ITP. <i>Oncology</i> , 2009 , 23, 1177-8	1.8	9
116	Refractory immune thrombocytopenic purpura: current strategies for investigation and management. <i>British Journal of Haematology</i> , 2008 , 143, 16-26	4.5	57
115	Overview of thrombopoietic agents in the treatment of thrombocytopenia. <i>Clinical Lymphoma and Myeloma</i> , 2008 , 8, 33-43		8
114	Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. <i>Health and Quality of Life Outcomes</i> , 2008 , 6, 13	3	69
113	Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. <i>Blood</i> , 2008 , 112, 1325-8	2.2	181
112	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. <i>Lancet, The</i> , 2008 , 371, 395-403	4.0	663
111	How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008 , 5, 424-5		2
110	The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. <i>Current Opinion in Oncology</i> , 2008 , 20, 690-6	4.2	11
109	Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. <i>Current Opinion in Pediatrics</i> , 2008 , 20, 8-16	3.2	26
108	Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2008 , 83, 150-4	7.1	110
107	Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. <i>Blood Reviews</i> , 2008 , 22, 33-52	11.1	74

106	Fc receptors in immune thrombocytopenias: a target for immunomodulation?. <i>Journal of Clinical Investigation</i> , 2008 , 118, 2677-81	15.9	19
105	Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE). <i>Blood</i> , 2008 , 112, 400-400	2.2	14
104	Self-Injection of Romiplostim by Patients with Chronic Immune Thrombocytopenic Purpura (ITP). <i>Blood</i> , 2008 , 112, 4707-4707	2.2	
103	Immune thrombocytopenic purpura. <i>Hematology/Oncology Clinics of North America</i> , 2007 , 21, 743-59, vii	3.1	56
102	A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. <i>Health and Quality of Life Outcomes</i> , 2007 , 5, 11	3	45
101	Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. <i>Journal of Allergy and Clinical Immunology</i> , 2007 , 120, 1178-85	11.5	137
100	Immune Thrombocytopenic Purpura 2007 , 831-845		2
99	Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. <i>American Journal of Hematology</i> , 2007 , 82, 335-41	7.1	12
98	Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2007 , 82, 192-8	7.1	10
97	Advances in the management of alloimmune thrombocytopenia. <i>British Journal of Haematology</i> , 2007 , 136, 366-78	4.5	57
96	The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. <i>British Journal of Haematology</i> , 2007 , 138, 245-8	4.5	112
95	Identifying babies with neonatal alloimmune thrombocytopenia and the responsible antigens. <i>Transfusion</i> , 2007 , 47, 6-7	2.9	4
94	Novel thrombopoietic agents. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 106-13	3.1	18
93	A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). <i>Blood</i> , 2007 , 109, 5527; author reply 5528	2.2	20
92	IVIg in ITP: no role for cytokines?. <i>Blood</i> , 2007 , 109, 4-5	2.2	
91	Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). <i>Blood</i> , 2007 , 110, 3526-31	2.2	75
90	New therapies for immune thrombocytopenic purpura. <i>Current Opinion in Hematology</i> , 2007 , 14, 427-31	3.3	12
89	Immune thrombocytopenic purpura in adults. <i>Current Opinion in Hematology</i> , 2007 , 14, 535-56	3.3	56

88	Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. <i>Obstetrics and Gynecology</i> , 2007 , 110, 249-55	4.9	60
87	Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. <i>New England Journal of Medicine</i> , 2007 , 357, 2237-47	59.2	610
86	R935788: A Phase II, Single Center, Open Label, Efficacy and Safety, Ascending Dose, Pilot Study for the Treatment of Adult Immune Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2007 , 110, 1310-1310	2.2	2
85	Evaluation of AMG 531 Efficacy in Nonsplenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study.. <i>Blood</i> , 2007 , 110, 565-565	2.2	5
84	Defective Circulating CD25 Regulatory T Cells in Patients with Chronic Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2007 , 110, 570-570	2.2	
83	Novel thrombopoietic agents: preliminary activity, potential benefit. <i>The Journal of Supportive Oncology</i> , 2007 , 5, 63-84		2
82	Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2006 , 81, 19-25	7.1	67
81	Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected children. <i>American Journal of Perinatology</i> , 2006 , 23, 487-92	3.3	28
80	AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. <i>New England Journal of Medicine</i> , 2006 , 355, 1672-81	59.2	414
79	Treatment of immune thrombocytopenic purpura in adults. <i>Seminars in Hematology</i> , 2006 , 43, S3-10; discussion S18-9	4	40
78	Review of therapies for immune thrombocytopenic purpura. <i>Seminars in Hematology</i> , 2006 , 43, S1-2	4	
77	When are platelets just platelets?. <i>Blood</i> , 2006 , 107, 3426-3427	2.2	1
76	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. <i>Blood</i> , 2006 , 107, 2639-42	2.2	183
75	Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. <i>Obstetrics and Gynecology</i> , 2006 , 107, 91-6	4.9	144
74	The pathogenesis of immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2006 , 133, 364-74	4.5	201
73	Alloimmune thrombocytopenia: state of the art 2006. <i>American Journal of Obstetrics and Gynecology</i> , 2006 , 195, 907-13	6.4	52
72	Insights into Therapeutic Mechanisms: Measuring Immature Platelet Fraction (IPF) Describes Response to Treatment in Immune Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2006 , 108, 1070-1070	2.2	3
71	GMA161 Treatment of Refractory ITP: Efficacy of FcγRIII Blockade.. <i>Blood</i> , 2006 , 108, 1074-1074	2.2	4

70	Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.. <i>Blood</i> , 2006 , 108, 475-475	2.2	11
69	Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.. <i>Blood</i> , 2006 , 108, 476-476	2.2	14
68	Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year.. <i>Blood</i> , 2006 , 108, 479-479	2.2	14
67	Velocardiofacial Syndrome (VCF): Presentation with and Management of Immune Cytopenias.. <i>Blood</i> , 2006 , 108, 3986-3986	2.2	
66	Development and Initial Validation of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ), a Disease-Specific Health-Related Quality of Life (HRQoL) Questionnaire.. <i>Blood</i> , 2006 , 108, 1078-1078	2.2	
65	Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. <i>Journal of Pediatrics</i> , 2005 , 146, 217-21	3.6	117
64	How I treat idiopathic thrombocytopenic purpura (ITP). <i>Blood</i> , 2005 , 106, 2244-51	2.2	285
63	Fetal and neonatal alloimmune thrombocytopenia in pregnancies involving in vitro fertilization: a report of four cases. <i>American Journal of Obstetrics and Gynecology</i> , 2005 , 192, 543-7	6.4	21
62	Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2005 , 45, 176-83	3	97
61	Response to Treatment of Helicobacter Pylori in Patients with Immune Thrombocytopenic Purpura: A Systematic Review and Metaanalysis.. <i>Blood</i> , 2005 , 106, 2151-2151	2.2	2
60	Re-Treatment with Rituximab in ITP: Comparison of Standard Dose with 2 Forms of Augmented Rituximab.. <i>Blood</i> , 2005 , 106, 1237-1237	2.2	1
59	Assessment of Bleeding in Thrombocytopenic Patients (pts) with Immune Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2005 , 106, 1255-1255	2.2	
58	Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura. <i>Haematologica</i> , 2005 , 90, 1715-6	6.6	7
57	Congenital and acquired thrombocytopenia. <i>Hematology American Society of Hematology Education Program</i> , 2004 , 2004, 390-406	3.1	61
56	Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcγRIIIa and FcγRIIIa polymorphisms. <i>British Journal of Haematology</i> , 2004 , 124, 511-8	4.5	76
55	The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2004 , 125, 232-9	4.5	238
54	Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. <i>American Journal of Hematology</i> , 2004 , 76, 205-13	7.1	169
53	Differential diagnosis and management of thrombocytopenia in childhood. <i>Pediatric Clinics of North America</i> , 2004 , 51, 1109-40, xi	3.6	21

52	IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. <i>Thrombosis and Haemostasis</i> , 2004 , 91, 771-8	7	45
51	Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura?. <i>Blood</i> , 2004 , 103, 890-6	2.2	127
50	Splenectomized Patients Have Reduced CD27+ Memory B Cells but Protective Antibody Responses to Pneumococcal Vaccination.. <i>Blood</i> , 2004 , 104, 3025-3025	2.2	1
49	Intravenous Immunoglobulin Manufactured Using a Novel Caprylate and Chromatography-Based Method (IGIV-C, Gamunex [®]) Was Safe and Well Tolerated When Administered at an Increased Maximum Rate in Patients with Idiopathic Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2004 , 104, 3027-3027	2.2	2
48	Fetal and neonatal cytopenias: what have we learned?. <i>American Journal of Perinatology</i> , 2003 , 20, 425-33	3	5
47	Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. <i>Journal of Pediatric Hematology/Oncology</i> , 2003 , 25, 660-4	1.2	102
46	Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents. <i>Journal of Pediatric Hematology/Oncology</i> , 2003 , 25, 56-62	1.2	46
45	Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). <i>American Journal of Hematology</i> , 2003 , 72, 94-8	7.1	124
44	Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. <i>British Journal of Haematology</i> , 2003 , 123, 142-6	4.5	58
43	High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2002 , 118, 836-8	4.5	16
42	Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?. <i>Blood</i> , 2002 , 99, 1922-7	2.2	79
41	Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. <i>Blood</i> , 2002 , 100, 1388-1398	2.2	115
40	Alloimmune thrombocytopenia 2002 , 569-583		
39	Another interaction of the FcR system with IVIG. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 890-1	7	6
38	A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2001 , 112, 1076-8	4.5	97
37	A pilot study of rhIL-11 treatment of refractory ITP. <i>American Journal of Hematology</i> , 2001 , 66, 172-7	7.1	49
36	Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy?. <i>American Journal of Hematology</i> , 2001 , 67, 27-33	7.1	36
35	Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. <i>American Journal of Obstetrics and Gynecology</i> , 2001 , 185, 976-80	6.4	32

34	Alloimmune thrombocytopenia in the fetus and newborn. <i>Seminars in Thrombosis and Hemostasis</i> , 2001 , 27, 245-52	5.3	48
33	Platelets: an update on diagnosis and management of thrombocytopenic disorders. <i>Hematology American Society of Hematology Education Program</i> , 2001 , 282-305	3.1	51
32	Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. <i>Journal of Pediatrics</i> , 2001 , 138, 862-7	3.6	71
31	Thrombocytopenia 2001 , 155-185		
30	A pilot study of rhIL-11 treatment of refractory ITP 2001 , 66, 172		3
29	Th1 and Th2 cytokines in a patient with Evans Syndrome and profound lymphopenia. <i>British Journal of Haematology</i> , 2000 , 110, 968-70	4.5	19
28	Fc receptor blockade and immune thrombocytopenic purpura. <i>Seminars in Hematology</i> , 2000 , 37, 261-6	4	66
27	Splenectomy-sparing strategies for the treatment and long-term maintenance of chronic idiopathic (immune) thrombocytopenic purpura. <i>Seminars in Hematology</i> , 2000 , 37, 1-4	4	15
26	Thrombocytopenia with absent radii: frequency of marrow megakaryocyte progenitors, proliferative characteristics, and megakaryocyte growth and development factor responsiveness. <i>Pediatric Hematology and Oncology</i> , 2000 , 17, 299-306	1.7	17
25	Fc receptor blockade and immune thrombocytopenic purpura. <i>Seminars in Hematology</i> , 2000 , 37, 261-266		51
24	Hematologic toxicity of sodium valproate. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000 , 22, 62-5		148
23	The Treatment of Patients with Autoimmune Thrombocytopenia with Intravenous IgG-Anti-D. <i>Vox Sanguinis</i> , 1999 , 76, 252-252	3.1	
22	Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV-1?. <i>American Journal of Hematology</i> , 1999 , 61, 94-7	7.1	4
21	Alloimmune thrombocytopenia. <i>Clinical Obstetrics and Gynecology</i> , 1999 , 42, 335-48	1.7	14
20	The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. <i>Best Practice and Research: Clinical Haematology</i> , 1998 , 11, 391-408		24
19	Fetal alloimmune thrombocytopenia. <i>New England Journal of Medicine</i> , 1997 , 337, 22-6	59.2	225
18	Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Experience in 272 Patients. <i>Blood</i> , 1997 , 89, 2689-2700	2.2	265
17	Antiplatelet antibody testing in thrombocytopenic pregnant women. <i>American Journal of Obstetrics and Gynecology</i> , 1996 , 174, 1014-8	6.4	54

16	Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. <i>American Journal of Obstetrics and Gynecology</i> , 1996 , 174, 1414-23	6.4	175
15	Serum levels of GM-CSF are elevated in patients with thrombocytopenia. <i>British Journal of Haematology</i> , 1996 , 92, 486-8	4.5	15
14	Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. <i>American Journal of Obstetrics and Gynecology</i> , 1995 , 172, 475-9	6.4	150
13	Evans Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 1995 , 17, 290-295	1.2	46
12	Accurate intrapartum estimation of fetal platelet count by fetal scalp samples smear. <i>American Journal of Perinatology</i> , 1994 , 11, 42-5	3.3	14
11	Favorable neurological outcome in 7 cases of perinatal intracranial hemorrhage due to immune thrombocytopenia. <i>Journal of Pediatric Hematology/Oncology</i> , 1991 , 13, 156-9	1.2	17
10	Estimation of the risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. <i>New England Journal of Medicine</i> , 1990 , 323, 229-35	59.2	182
9	Isolated thrombocytopenia in patients infected with HIV: treatment with intravenous gammaglobulin. <i>American Journal of Hematology</i> , 1988 , 28, 79-84	7.1	40
8	The in utero diagnosis and management of alloimmune thrombocytopenia. <i>Prenatal Diagnosis</i> , 1988 , 8, 329-31	3.2	18
7	Antenatal treatment of neonatal alloimmune thrombocytopenia. <i>New England Journal of Medicine</i> , 1988 , 319, 1374-8	59.2	287
6	Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. <i>New England Journal of Medicine</i> , 1986 , 314, 1236-9	59.2	321
5	Therapy in cytopenia. <i>Vox Sanguinis</i> , 1986 , 51 Suppl 2, 69-73	3.1	8
4	Intravenous immune serum globulin in immune thrombocytopenia: clinical results and biochemical evaluation. <i>Vox Sanguinis</i> , 1985 , 49 Suppl 1, 44-50	3.1	19
3	A heparin-like anticoagulant in an 8-month-old boy with acute monoblastic leukemia. <i>American Journal of Hematology</i> , 1984 , 16, 83-90	7.1	49
2	Intravenous use of gammaglobulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy. <i>Journal of Pediatrics</i> , 1983 , 103, 651-4	3.6	100
1	Fetal and neonatal immune thrombocytopenia 141-156		